GlobalRPh Renal Dosing Masterv6.6
Source review / handoff

Empagliflozin (Jardiance)

One or two intact local summaries. No averaged regimen, patient-specific dose or automatic source preference.

Return to full drug recordRead selected sourcesHow to use this review

Selecting here opens the current stored cards. The pinned link below records their fingerprints. Do not enter patient information in links or searches.

Share or print this source review

1 local source card selected. Local card fingerprints checked where supplied. This is not an original-document hash, source-currency guarantee or clinical approval. Record-level cautions below are the current library's cautions, not a frozen prior version.

Copy is optional; the link can be selected and copied manually. No patient data or dose decision is collected.

Clinical context remains essential

Independent clinical review is pending. Confirm indication, exact formulation/route, population, renal measure and units, kidney-function stability, dialysis prescription, interacting drugs, monitoring and source revision. An RX mirror and its original label are not independent corroboration. Missing disagreement notes do not certify agreement.

The preserved GlobalRPh and 2019 handbook thresholds concern older glucose-lowering use. They are not current blanket exclusion rules for the separately labeled heart-failure and CKD indications.

Check source scope before reading a dose

Renal Drug Handbook, fifth edition

Product / population
Historical 2019 reference; renal bands retain the book's own method labels.
Renal method
Not specified
Source revision
Not established
Retrieved
2026-09-05
Local review status
Historical handbook facts locally summarized; not a current U.S. label or a modern CRRT protocol.
Handbook

Renal Drug Handbook, fifth edition

UK Renal Pharmacy Group / Ashley and Dunleavy / CRC Press · Historical 2019 reference; renal bands retain the book's own method labels.

Renal method: Not specified in this summary.
Source date: Not established
Retrieved: 2026-09-05

Historical handbook facts locally summarized; not a current U.S. label or a modern CRRT protocol.

Historical glucose-lowering thresholds

The book lists 10 mg daily at GFR 45-60 mL/min and avoidance below 45. It advises against starting below indexed eGFR 60 and discontinuation for persistent values below 45.

general-empagliflozin:rdh5-362-1 · Source locator: Dose in renal impairment; Other information

Historical renal-replacement comments

APD/CAPD, HD, high-flux HDF and CAV/VVHD are all marked avoid, with removal considered unlikely. Small pharmacokinetic studies are discussed but do not establish outcome evidence for routine dialysis initiation.

general-empagliflozin:rdh5-362-2 · Source locator: Dose in renal replacement; Other information

Source-specific limits

These 2019 glucose-lowering thresholds predate the currently selected U.S. label's heart-failure and CKD indications. They must not be used as a current all-indication exclusion rule.

Source identity and provenance
Retrieved
2026-09-05
Handbook page
Printed page 362; PDF page 381
Hash meaning
Locally authored source summary, not original SPL/XML/PDF bytes
Local summary SHA-256
f396b795f4c01b716b584be33c1ca4dd70c3e64105d312bce6b1e1abb62b8ed8

Document the clinical decision separately

This reference does not select a regimen. Complete the indication, measured/estimated renal function and trend, dialysis setting, source rationale, monitoring and reassessment plan in your institution's approved documentation system. Confirm the complete current source before adopting its regimen.

GlobalRPh v6.6 | RDM66-DIRECT-PHP-20260911 | Local library date 2026-09-11. Selected-card identity does not imply clinical verification.

Pinned reference: https://globalrph.com/blogCalcs/renal-dosing-master/compare.php?id=general-empagliflozin&s1=rdh5-362&h1=3090d10709994b7fe3d629ceaa86f23213376ffe05adf4df2df4d4899773d9b6